Enasidenib

Updates on IDH inhibition in AML 3:14
Updates on IDH inhibition in AML
Amir Fathi • 24 Jun 2021
Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246 5:05
Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246
Valeria Santini • 25 Jan 2021
MDS clinical trials: the European effort 4:17
MDS clinical trials: the European effort
Valeria Santini • 25 Jan 2021
Enasidenib plus azacitidine in newly-diagnosed AML 1:24
Enasidenib plus azacitidine in newly-diagnosed AML
Eytan Stein • 2 Dec 2020
AML post-transplant maintenance: enasidenib & ivosidenib 2:49
AML post-transplant maintenance: enasidenib & ivosidenib
Amir Fathi • 24 Nov 2020
AML: new targeted inhibitors as single agents? 1:42
AML: new targeted inhibitors as single agents?
Christoph Röllig • 26 Jun 2020
Enasidenib for IDH2-mutated MDS 1:13
Enasidenib for IDH2-mutated MDS
Valeria Santini • 17 Mar 2020
Progress in AML & research at the University of Düsseldorf 1:27
Progress in AML & research at the University of Düsseldorf
Thomas Schröder
Personalized AML therapy with John Byrd: the beat AML trial and more 4:31
Personalized AML therapy with John Byrd: the beat AML trial and more
John Byrd
Ivosidenib or enasidenib with chemotherapy for AML produces deep remissions 2:52
Ivosidenib or enasidenib with chemotherapy for AML produces deep remissions
Eytan Stein
Beat AML: promising results with enasidenib for AML in the frontline 2:25
Beat AML: promising results with enasidenib for AML in the frontline
Eytan Stein
IDH inhibitors for AML: highlights from ASH 2018 1:25
IDH inhibitors for AML: highlights from ASH 2018
Marina Konopleva
IDH1/2 inhibitors for upfront AML therapy and transfusion independence 1:51
IDH1/2 inhibitors for upfront AML therapy and transfusion independence
Amir Fathi
Gene-based treatments show positive outcomes in AML 4:42
Gene-based treatments show positive outcomes in AML
Harry Erba • 12 Sep 2018
Gene-targeting therapies for AML 4:06
Gene-targeting therapies for AML
Harry Erba
The promising role of IDH inhibitors in AML 1:53
The promising role of IDH inhibitors in AML
Amir Fathi
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals